NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CRSP

CRISPR Therapeutics AG

Apr 17 • 04:00PM ET

37.77

Dollar change -0.01
Percentage change -0.03	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: EDIT NTLA BEAM SGMO VRTX GILD BLUE ALLO CLLS ADPT

| Held by: ARKK ARKG XBI VXF IBB SCHA XT VHT SCHM LABU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.36	Insider Own	4.33%	Shs Outstand	85.74M	Perf Week	10.25%
Market Cap	3.26B	Forward P/E	-	EPS next Y	-3.99	Insider Trans	-3.30%	Shs Float	82.46M	Perf Month	-9.94%
Income	-366.25M	PEG	-	EPS next Q	-1.22	Inst Own	69.09%	Short Float	24.87%	Perf Quarter	-6.28%
Sales	37.31M	P/S	87.25	EPS this Y	-11.69%	Inst Trans	2.78%	Short Ratio	8.84	Perf Half Y	-21.39%
Book/sh	22.53	P/B	1.68	EPS next Y	17.65%	ROA	-16.38%	Short Interest	20.51M	Perf Year	-34.83%
Cash/sh	22.09	P/C	1.71	EPS next 5Y	13.89%	ROE	-19.20%	52W Range	30.04 - 67.88	Perf YTD	-4.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-17.13%	52W High	-44.36%	Beta	1.77
Dividend TTM	-	Quick Ratio	22.07	Sales past 5Y	31550.17%	Gross Margin	-247.24%	52W Low	25.73%	ATR (14)	2.54
Dividend Ex-Date	-	Current Ratio	22.07	EPS Y/Y TTM	-123.71%	Oper. Margin	-1250.38%	RSI (14)	49.46	Volatility	6.49% 6.61%
Employees	393	Debt/Eq	0.12	Sales Y/Y TTM	-89.95%	Profit Margin	-981.54%	Recom	1.97	Target Price	80.20
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	-139.74%	Payout	-	Rel Volume	0.44	Prev Close	37.78
Sales Surprise	343.09%	EPS Surprise	63.35%	Sales Q/Q	-82.26%	Earnings	Feb 11 AMC	Avg Volume	2.32M	Price	37.77
SMA20	3.34%	SMA50	-7.97%	SMA200	-18.04%	Trades		Volume	1,027,121	Change	-0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform	$60 → $99
Feb-12-25	Upgrade	TD Cowen	Sell → Hold	$35
Feb-03-25	Initiated	H.C. Wainwright	Buy	$65
Aug-06-24	Reiterated	Needham	Buy	$88 → $84
Aug-02-24	Initiated	Rodman & Renshaw	Buy	$90
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform	$30
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight	$99 → $88
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line	$66 → $60
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$98

Show Previous Ratings

Today 09:15AM	5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years (Motley Fool)
Apr-17-25 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-12-25 02:45PM	3 Magnificent Stocks That Could Double or More by 2030 (Motley Fool)
Apr-11-25 03:45AM	Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool) +14.71%
Apr-10-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know (Zacks)
09:00AM	Loading…
Apr-09-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks) +11.58%
Apr-08-25 03:29PM	CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript) (Seeking Alpha)
Apr-07-25 08:09AM	4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street (Motley Fool)
07:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Apr-04-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know (Zacks)
Apr-03-25 09:30AM	Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March (Motley Fool)
08:00AM	CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
Mar-31-25 04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily) -8.00%
03:25PM	Loading…
03:25PM	Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today (Motley Fool)
10:10AM	Intellia Focuses on Pipeline Development Amid Stiff Competition (Zacks)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks)
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
07:01AM	Novo gains Lexicon obesity drug; CRISPR COO to step down (BioPharma Dive)
Mar-26-25 04:01PM	CRISPR Therapeutics Announces Transition of Chief Operating Officer (GlobeNewswire)
Mar-25-25 05:40PM	Is CRISPR Therapeutics AG (CRSP) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
11:03AM	CRISPR Therapeutics Set To Reach Previous Heights (SeekingAlpha)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Mar-22-25 04:04PM	2 Beaten-Down Stocks to Buy on the Dip (Motley Fool)
Mar-21-25 05:50PM	CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
08:00AM	As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point (Investor's Business Daily)
Mar-20-25 06:00PM	CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors (Zacks)
02:59AM	Intel And Crispr: 2 'Bond-Like' Option Trades Yielding 13%+ (SeekingAlpha)
06:10PM	Loading…
Mar-19-25 06:10PM	2 No-Brainer Biotech Stocks to Buy Right Now (Fool)
02:39PM	Is CRISPR Therapeutics (CRSP) One of the Most Shorted Stocks in 2025? (Insider Monkey)
10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
09:41AM	CRISPR Therapeutics AG (CRSP): A Bull Case Theory (Insider Monkey)
Mar-18-25 10:41AM	CRISPR Therapeutics (CRSP): Among Top Stocks to Buy from Ark Invest's Portfolio (Insider Monkey)
Mar-14-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-13-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report? (Zacks)
Mar-11-25 08:35AM	ElevateBio taps Amazons genAI tools to design CRISPR therapeutics (Pharmaceutical Technology)
Mar-03-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-28-25 03:15AM	3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. (Motley Fool)
Feb-26-25 08:00AM	CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-24-25 10:00AM	2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street (Motley Fool)
Feb-23-25 01:34PM	CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:01PM	CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Feb-16-25 05:34AM	Street Calls of the Week (Investing.com)
Feb-15-25 02:00AM	Why CRISPR Therapeutics (CRSP) Soared on Friday? (Insider Monkey)
Feb-14-25 12:20PM	CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99 (GuruFocus.com) +14.33%
10:38AM	CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment (GuruFocus.com)
Feb-12-25 06:37PM	Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday (Motley Fool) +9.29%
11:26AM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
10:25AM	Crispr Therapeutics price target raised to $86 from $85 at BofA (TipRanks)
Feb-11-25 05:10PM	CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-10-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know (Zacks)
06:15AM	Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move (Motley Fool)
Feb-06-25 08:13PM	CRISPR Therapeutics AG (CRSP): Among Cathie Woods Top Stock Picks for 2025 (Insider Monkey)
Feb-04-25 06:00PM	Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today (Zacks)
Jan-30-25 01:50PM	Jim Cramer Says CRISPR (CRSP) Keeps Losing Money Like Moderna Heres Why (Insider Monkey)
Jan-29-25 05:50PM	CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors (Zacks)
08:00AM	CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-24-25 06:00PM	CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Jan-23-25 08:30AM	CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last? (Zacks)
04:15AM	My Top 5 Stocks to Buy in Early 2025 (Motley Fool)
Jan-17-25 11:16AM	CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-16-25 08:00AM	2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows (Motley Fool)
03:15AM	My 10 Top Stocks to Buy to Start the New Year Off Right (Motley Fool)
Jan-14-25 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
04:34AM	Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts (Motley Fool)
Jan-13-25 07:00AM	CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones (GlobeNewswire)
Jan-09-25 04:20AM	3 Mid-Cap Stocks That Could Take Off in 2025 (Motley Fool)
Jan-08-25 08:30AM	CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 06:00PM	CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
08:00AM	CRISPR Therapeutics Proposes New Appointment to the Board of Directors (GlobeNewswire)
07:19AM	Vertex, startup Orna to partner on gene editing research (BioPharma Dive)
Dec-31-24 05:50PM	CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know (Zacks) +5.26%
Dec-30-24 03:47PM	Why Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-29-24 06:36AM	CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-26-24 06:00PM	CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors (Zacks)
Dec-22-24 12:25PM	This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? (Motley Fool)
Dec-20-24 09:30AM	1 Big New Green Flag for CRISPR Therapeutics' Stock (Motley Fool)
Dec-17-24 05:29AM	2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? (Motley Fool)
Dec-14-24 09:45AM	3 Things You Need to Know if You Buy CRISPR Therapeutics Today (Motley Fool)
Dec-12-24 12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-11-24 11:45AM	Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers? (Insider Monkey)
Dec-09-24 12:00PM	CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-07-24 08:45AM	2 Biotech Stocks to Buy Hand Over Fist in December (Motley Fool)
Dec-06-24 12:00PM	CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.70%
Dec-05-24 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report? (Zacks)
05:27AM	3 of the Best Growth Stocks You Can Buy for Less than $100 (Motley Fool)
Dec-02-24 05:44PM	Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet (Zacks) +7.78% -7.09%
Nov-30-24 04:35AM	Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65% (Motley Fool)
Nov-24-24 05:47AM	Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? (Motley Fool)
Nov-23-24 06:30AM	3 Monster Stocks in the Making (Motley Fool)
Nov-21-24 05:15PM	Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 07:03PM	CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-18-24 06:53AM	CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest (BioPharma Dive)
Nov-17-24 05:11PM	CRISPR Therapeutics AG (CRSP): Among ARK Invest's Top Stock Picks for 2024 (Insider Monkey)
Nov-16-24 06:00AM	2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More (Motley Fool)
Nov-15-24 05:45AM	Where Will CRISPR Therapeutics Be in 3 Years? (Motley Fool)

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kulkarni Samarth	Chief Executive Officer	Mar 21 '25	Sale	41.23	10,031	413,578	195,085	Mar 24 05:35 PM
Bruno Julianne	Chief Operating Officer	Mar 21 '25	Sale	41.23	1,714	70,668	10,544	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 21 '25	Sale	41.23	2,197	90,582	16,767	Mar 24 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 21 '25	Sale	41.23	3,185	131,318	81,729	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 17 '25	Sale	41.80	3,762	157,252	12,714	Mar 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Mar 11 '25	Sale	42.42	9,973	423,055	180,890	Mar 12 07:05 PM
Kulkarni Samarth	Chief Executive Officer	Mar 12 '25	Sale	43.32	4,462	193,294	185,428	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 11 '25	Sale	42.42	2,850	120,897	77,530	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 12 '25	Sale	43.32	1,116	48,345	78,664	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 11 '25	Sale	42.42	1,198	50,819	8,263	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 12 '25	Sale	43.32	190	8,231	8,508	Mar 12 07:05 PM
Greene John	Director	Feb 26 '25	Buy	44.85	7,000	313,948	7,000	Feb 28 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	55.20	18,360	1,013,564	171,613	Feb 21 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 18 '25	Sale	55.05	11,640	640,782	196,901	Feb 19 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	52.80	6,928	365,798	189,973	Feb 19 05:35 PM
Bruno Julianne	Chief Operating Officer	Feb 19 '25	Sale	52.80	333	17,582	7,062	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 18 '25	Sale	53.85	9,595	516,691	73,002	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 19 '25	Sale	52.80	1,947	102,802	74,880	Feb 19 05:35 PM
Samarth Kulkarni	Officer	Feb 18 '25	Proposed Sale	52.22	45,000	2,349,900		Feb 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Dec 24 '24	Option Exercise	16.21	13,751	222,904	195,291	Dec 27 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Dec 02 '24	Sale	55.10	15,000	826,564	181,540	Dec 04 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Nov 11 '24	Sale	55.62	30,000	1,668,678	196,540	Nov 13 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 14 '24	Sale	46.28	1,089	50,399	62,597	Oct 15 06:00 PM
Kulkarni Samarth	Chief Executive Officer	Oct 14 '24	Sale	46.28	4,293	198,680	226,540	Oct 15 06:00 PM
Bruno Julianne	Chief Operating Officer	Jun 21 '24	Sale	56.09	3,366	188,799	6,745	Jun 24 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRSP

CRISPR Therapeutics AG

Upgrade your FINVIZ experience